Zalicus Inc

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Zalicus Inc - overview

Established

2000

Location

Cambridge, MA, US

Primary Industry

Biotechnology

About

Zalicus Inc, operating under the brand CombinatorX, focuses on delivering innovative technological solutions, particularly advanced software platforms aimed at optimizing business operations across diverse industries. Founded in 2000 and headquartered in Cambridge, US, Zalicus Inc (CombinatorX) specializes in developing technological solutions for businesses. In March 2006, the company underwent a Trade Sale raising USD 8. 00 mn from Horizon Discovery Ltd.


The firm has completed a total of 14 deals, with its most recent deal dated March 24, 2006. Zalicus was formed through the entrepreneurial vision of its founders, who recognized the need for advanced operational solutions in various sectors. CombinatorX specializes in the development and provision of innovative technological solutions designed to streamline operations across various sectors. Their core product offerings focus on advanced software platforms that cater to the needs of businesses seeking to optimize workflows, enhance productivity, and improve overall operational efficiency.


The company targets a diverse array of industries, including healthcare, finance, and logistics, with solutions aimed at addressing specific challenges such as data management, regulatory compliance, and resource allocation. CombinatorX's products are designed for use by corporations, small to medium enterprises, and government agencies, ensuring a broad client base that spans multiple geographical markets, including North America, Europe, and parts of Asia. By continuously evolving their offerings based on user feedback and market demands, CombinatorX strives to maintain a competitive edge in the rapidly changing technology landscape. In the most recent financial year of 2013, CombinatorX reported a revenue of USD 14.


73 mn and an EBITDA of USD -27. 16 mn. The company generates revenue through a combination of subscription-based models and B2B partnership agreements, with clients typically engaging in multi-year contracts that provide access to a suite of tailored software applications. This recurring revenue model fosters long-term relationships with clients across various sectors.


Zalicus Inc plans to launch new product offerings aimed at enhancing their software solutions, although specific release dates remain undisclosed. The company is targeting expansion into new geographic markets, particularly in Europe and parts of Asia by the end of 2024. Recent funding from the Trade Sale will be utilized to support these initiatives and strengthen product development efforts, building on the success of their previous IPO where they raised USD 42 mn.


Current Investors

Boston Millennia Partners, Flagship Pioneering, TL Ventures

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Epidemiology, Oncology/Cancer Treatment

Website

www.combinatorx.com

Company Stage

Mature

Total Amount Raised

Subscriber access only

Zalicus Inc - financials

Fiscal Year EndedDec 31, 2010Dec 31, 2011Dec 31, 2012Dec 31, 2013
Revenue (USD)46,741,000---
% Revenue Growth (YoY)----
EBITDA (USD)14,042,000---
Operating Income (USD)(7,121,000)---
Operating Margin(15.2%)---
% EBITDA Margin30.0%---
NET Income (USD)(35,045,000)---
% Net Margin(75.0%)---

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.